NASDAQ:ATNX Athenex (ATNX) Stock Price, News & Analysis → $16T Crypto Plot From Elon Musk (From Crypto 101 Media) (Ad) Free ATNX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.20▼$1.5252-Week Range N/AVolume1.88 million shsAverage Volume194,316 shsMarket Capitalization$1.76 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Athenex alerts: Email Address Ad Daily Market AlertsTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world's most powerful tech companies (including Microsoft, Intel, and Google) investing billions. And one tiny company will be the driving force behind this new tech revolution…Click below for your free report "Top 5 Tech Stocks to Buy in 2024", About Athenex Stock (NASDAQ:ATNX)Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.Read More Ad Daily Market AlertsTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world's most powerful tech companies (including Microsoft, Intel, and Google) investing billions. And one tiny company will be the driving force behind this new tech revolution…Click below for your free report "Top 5 Tech Stocks to Buy in 2024", ATNX Stock News HeadlinesDecember 26, 2023 | bizjournals.comBiopharmaceutical company expands in time to take on Athenex businessNovember 22, 2023 | bizjournals.comOnly 2 local CEOs score highly with both employees and investorsJuly 31, 2023 | bizjournals.comAthenex assets sold in bankruptcy auction; top executives dismissedJune 11, 2023 | fool.comAthenex (NASDAQ: ATNX)June 1, 2023 | bizjournals.comBuffalo's drug development scene expected to continue in Athenex's wakeMay 17, 2023 | bizjournals.comAthenex to lay off 123 WNY employees, close both Buffalo-area plants by mid-AugustMay 16, 2023 | uk.finance.yahoo.comAthenex, Inc. (ATNX) stock price, news, quote & history – Yahoo FinanceMay 16, 2023 | msn.comBuffalo Billion project Athenex files for Chapter 11 bankruptcyMay 15, 2023 | msn.comAthenex files Chapter 11May 15, 2023 | bizjournals.comAthenex files for bankruptcy, announces plans to sell assetsMay 15, 2023 | msn.comWhy Athenex (ATNX) Stock Is Getting Obliterated MondayMay 15, 2023 | finance.yahoo.comAthenex Voluntarily Filed For Chapter 11 Proceedings, Shares PlungeMay 15, 2023 | marketwatch.comAthenex Shares Tumble Premarket After Chapter 11 Filing >ATNXMay 15, 2023 | msn.comWhy Is Athenex (ATNX) Stock Down 54% Today?May 15, 2023 | markets.businessinsider.comAthenex Files For Chapter 11 BankruptcyMay 14, 2023 | news.yahoo.comDrugmaker Athenex voluntarily files for U.S. Chapter 11 proceedingsMay 14, 2023 | finance.yahoo.comAthenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales ProcessMay 10, 2023 | bizjournals.comPine Pharmaceuticals assumes part of Athenex’s business and 50 workersMay 1, 2023 | finance.yahoo.comQuantum Leap Healthcare Collaborative Announces Result of Oral Paclitaxel in Combination with a PD-1 and Carboplatin from I-SPY2 TRIAL at ASCOApril 24, 2023 | finance.yahoo.comAthenex, Inc. (ATNX) Stock Historical Prices & Data - Yahoo FinanceApril 18, 2023 | bizjournals.comCalifornia-based Biomed Industries offers to buy AthenexMarch 23, 2023 | finance.yahoo.comAthenex (ATNX) Upgraded to Buy: Here's WhyFebruary 14, 2023 | finance.yahoo.comAthenex Announces a Reverse Stock SplitJanuary 3, 2023 | finance.yahoo.comAthenex Announces MHRA Decision on Oral PaclitaxelDecember 31, 2022 | msn.comAthenex to close Clarence plant, lay off 92 employeesSee More Headlines Receive ATNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Athenex and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today6/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ATNX CUSIPN/A CIK1300699 Webwww.athenex.com Phone(716) 427-2950FaxN/AEmployees652Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($15.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-103,430,000.00 Net Margins-86.31% Pretax Margin-95.92% Return on Equity-727.79% Return on Assets-44.44% Debt Debt-to-Equity Ratio3.08 Current Ratio1.09 Quick Ratio0.72 Sales & Book Value Annual Sales$102.82 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($3.07) per share Price / BookN/AMiscellaneous Outstanding Shares8,660,000Free Float7,866,000Market Cap$1.76 million OptionableOptionable Beta1.36 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesYiu Nam LauChairman & Chief Executive OfficerJeff YordonCOO & President-Athenex Pharmaceutical DivisionJoe AnnoniChief Financial OfficerDarrel P. CohenChief Medical OfficerWilliam ZuoPresident-China OperationsKey CompetitorsPulmatrixNASDAQ:PULMASLAN PharmaceuticalsNASDAQ:ASLNTenax TherapeuticsNASDAQ:TENXHepion PharmaceuticalsNASDAQ:HEPASunshine BiopharmaNASDAQ:SBFMView All Competitors ATNX Stock Analysis - Frequently Asked Questions How were Athenex's earnings last quarter? Athenex, Inc. (NASDAQ:ATNX) announced its quarterly earnings data on Thursday, November, 4th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.41) by $0.08. The business had revenue of $32.30 million for the quarter, compared to analysts' expectations of $19.40 million. Athenex had a negative net margin of 86.31% and a negative trailing twelve-month return on equity of 727.79%. During the same period last year, the firm posted ($0.44) earnings per share. What other stocks do shareholders of Athenex own? Based on aggregate information from My MarketBeat watchlists, some companies that other Athenex investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), QUALCOMM (QCOM), Amarin (AMRN), AbbVie (ABBV), Gilead Sciences (gild), OPKO Health (OPK) and Sorrento Therapeutics (SRNE). When did Athenex IPO? Athenex (ATNX) raised $72 million in an initial public offering on Wednesday, June 14th 2017. The company issued 6,000,000 shares at $11.00-$13.00 per share. Credit Suisse, Deutsche, Bank Securities and J.P. Morgan acted as the underwriters for the IPO and ICBC International was co-manager. This page (NASDAQ:ATNX) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredBiden out June 13; replacement chosen?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athenex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Athenex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.